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Excitatory and inhibitory neurotransmission is chronically altered following
perinatal NMDA receptor blockade
Abstract
N-methyl-d-aspartate (NMDA) receptor blockade in rodents induces behavioural and neurochemical
changes reminiscent of schizophrenia symptoms and pathology. To examine how NMDA receptor
blockade affects glutamatergic and GABAergic pathways when administered during early brain
development, [3H]MK-801 and [3H]muscimol binding to NMDA and GABAA receptors was examined at
four time-points following injections of phencyclidine (PCP) or saline on postnatal days (PN)7, 9 and 11.
[3H]MK-801 binding was significantly increased in PCP-treated rats in the thalamus from PN18 to PN96,
in the prefrontal and anterior cingulate cortices at PN32, and in the hippocampus at PN96. In a similar
manner, [3H]muscimol binding was increased in PCP-treated rats in the thalamus and hippocampus from
PN18 to PN96, and in the prefrontal and anterior cingulate cortices at PN32. Glutamatergic and
GABAergic transmission is therefore chronically altered by this treatment, which has relevance to disease
processes that may be involved in schizophrenia.
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ABSTRACT
N-methyl-D-aspartate (NMDA) receptor blockade in rodents induces behavioural and
neurochemical changes reminiscent of schizophrenia symptoms and pathology. To
examine how NMDA receptor blockade affects glutamatergic and GABAergic
pathways when administered during early brain development, [3H]MK-801 and
[3H]muscimol binding to NMDA and GABAA receptors was examined at four timepoints following injections of phencyclidine (PCP) or saline on postnatal days (PN)7,
9 and 11. [3H]MK-801 binding was significantly increased in PCP-treated rats in the
thalamus from PN18 to PN96, in the prefrontal and anterior cingulate cortices at
PN32, and in the hippocampus at PN96. In a similar manner, GABAA receptor
binding was increased in PCP-treated rats in the thalamus and hippocampus from
PN18 to PN96, and in the prefrontal and anterior cingulate cortices at PN32.
Glutamatergic and GABAergic transmission is therefore chronically altered by this
treatment, which has relevance to disease processes that may be involved in
schizophrenia.

Key words: brain development, GABAA receptor, NMDA receptor, phencyclidine,
schizophrenia
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1. INTRODUCTION
Glutamate, predominantly through its actions on N-methyl-D-aspartate (NMDA)
receptors, plays a key role in brain developmental processes such as neuronal
migration, synaptogenesis and synaptic plasticity (McDonald and Johnston 1990;
Pearce et al. 1987). The timing of expression of glutamate receptors appears to be
crucial for normal brain development, since changes in the activity of glutamate
receptors may interfere with these processes (Ritter et al. 2001; Ritter et al. 2002).

During development in the rat, particularly postnatal days (PN)7–14, the brain is
highly sensitive to the toxic effects of modulation of the NMDA receptor (Haberny et
al. 2002), which may relate to the increased expression of specific NMDA receptor
subunits (Mitani et al. 1998). Given the important role of the NMDA receptor in brain
developmental processes, antagonism of this receptor could have severe long-term
detrimental effects such as reduced and/or non-functional neuronal connections
(Behar et al. 1999).

In rodents, treatment with NMDA receptor antagonists such as phencyclidine (PCP)
and MK-801 during the perinatal period induces neuronal apoptosis (Fredriksson et al.
2004; Hansen et al. 2004; Harris et al. 2003; Ikonomidou et al. 1999; Wang et al.
2001). In the long-term, perinatal NMDA receptor blockade impairs cognitive
function (Andersen and Pouzet 2004; Sircar 2003; Stefani and Moghaddam 2005;
Wang et al. 2001; Wiley et al. 2003), sensorimotor gating (Harris et al. 2003; Wang et
al. 2001; Wang et al. 2003) and locomotor activity (du Bois et al. 2008b; Facchinetti
et al. 1993; Wang et al. 2001), which are particularly relevant to schizophrenia
symptoms and pathology. Abnormal expression of neurotransmitter receptors
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including dopamine D2 (du Bois et al. 2008a; Sircar and Soliman 2003) and NMDA
(Harris et al. 2003; Wang et al. 2001; Wilson et al. 1998) is a further long-term
consequence of perinatal NMDA receptor blockade. Recently it was shown that
perinatal PCP treatment caused a selective loss of parvalbumin-containing
(GABAergic) neurons in the cortex of rats at adulthood (Wang et al. 2007).

Hypofunction of NMDA receptors has been implicated in schizophrenia, since
NMDA receptor anatgonists such as PCP and ketamine mimic schizophrenia
symptoms so well in healthy individuals and strongly exacerbate symptoms in
schizophrenia patients (Javitt and Zukin 1991). However, post mortem studies of the
binding site of the NMDA receptor have revealed inconsistent results. Increased
[3H]MK-801 binding has been reported in the anterior and posterior cingulate cortices
(Newell et al. 2005; Zavitsanou et al. 2002), superior temporal gyrus (Nudmamud and
Reynolds 2001) and putamen (Kornhuber et al. 1989) of schizophrenia patients versus
controls, while binding was reported as unchanged in other areas including the frontal
and entorhinal cortices, hippocampus and amygdala (Kornhuber et al. 1989).
Conversely, decreased NMDA receptor binding has been observed in the
hippocampus (Dean et al. 1999), using [3H]TCP.

Findings also point to a deficit in GABAergic transmission in schizophrenia.
Decreased GAD67, a marker for GABAergic terminals, has been found in the
prefrontal cortex (Akbarian et al. 1995; Guidotti et al. 2000; Volk et al. 2000).
Reductions of GABAergic interneurons have been found in anterior cingulate and
prefrontal cortices and hippocampus (Benes et al. 1998; Benes et al. 1991). Moreover,
reductions of parvalbumin-containing interneurons have been reported in superficial
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layers of the prefrontal cortex (Beasley and Reynolds 1997; Reynolds et al. 2002).
Deficits in GABA synthesis and release may therefore contribute to the observed
increase in [3H]muscimol binding in several brain regions (Benes et al. 1992; Benes et
al. 1996; Deng and Huang 2006; Newell et al. 2007).

Along with perinatal PCP treatment of rodents, another developmental model of
schizophrenia (prenatal methylazoxymethanol acetate (MAM) administration) has
shown decreased parvalbumin-containing interneurons (Lodge et al. 2008), suggesting
that common targets and pathways contribute to the schizophrenia-like pathology in
these animal models. The fact that these models alter the expression of parvalbumincontaining (GABAergic) neurons has important construct validity, as disinhibition of
pyramidal neurons from reduced GABAergic activity is thought to contribute to
schizophrenia pathology (Lisman et al. 2008). To further investigate alterations to key
pathways implicated in schizophrenia, we investigated NMDA and GABAA receptor
binding in various brain regions of rats at several time-points following perinatal PCP
exposure, to determine if interruption to NMDA receptor function early in
development can have persistent long-term consequences on brain function. We
hypothesised that changes in NMDA receptor expression would tightly influence
expression of GABAA receptors in brain regions examined.

2. EXPERIMENTAL PROCEDURES
2.1 Animals
Timed pregnant Sprague-Dawley rats were obtained at gestation day 14 from the
Animal Resource Centre (Perth, WA, Australia). They were housed individually
under a 12:12-hour light-dark cycle in a temperature controlled environment. Food

5

du Bois et al.
and water was freely available. Day of birth was considered postnatal day (PN)0.
Pups were sexed on PN7 and litters were assigned to PCP or saline groups (5
litters/group). Male pups were kept in the litters until weaning but were not treated.
Pups were weaned at PN24-28 and were then housed in pairs. Female rats were used
because the literature shows that treating female rat pups on PN7, 9 and 11 with PCP
produces apoptosis and alterations in sensorimotor gating, motor activity and working
memory (Wang et al. 2001; Wiley et al. 2003), all of which have particular relevance
to schizophrenia symptoms and pathology. This study was approved by the Animal
Ethics Committee of the University of Wollongong, and procedures complied with the
Australian Code of Practice for the Care and Use of Animal for Scientific Purposes,
which conforms to International Guiding Principles for Biomedical Research
Involving Animals. All efforts were made to minimize numbers of animals used and
their suffering.

2.2 Perinatal PCP treatment
On PN7, 9 and 11, pups were given a subcutaneous injection of 10 mg/kg
phencyclidine hydrochloride (Sigma, Castle Hill, NSW, Australia) or 0.9% NaCl at a
volume of 1 ml/kg. Six rats from each group (PCP and control) were sacrificed at four
different time-points (24 hr, 1 week, 3 weeks or 12 weeks) following their last
injection for biochemical analyses, representing juvenile (PN12 and 18), adolescent
(PN32) and adult (PN96) ages.

2.3 Histology
Rats were sacrificed by carbon dioxide asphyxiation and brains were removed and
frozen in liquid nitrogen immediately after extraction. Brain tissue was kept at -80°C
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until sectioning. Brains were cut into 14 µm coronal sections with a cryostat at -18oC,
and were mounted on PolysineTM microscope slides. Sections were collected at levels
approximately corresponding to bregma 3.70 and -5.20 mm, with the aid of a standard
rat brain atlas (Paxinos and Watson 1986). Tissue sections were stored at -20oC until
further use.

2.4 NMDA receptor binding
The method for NMDA receptor binding was taken from Newell et al. (2005).
Sections were incubated at room temperature for 2.5 hr in 30 mM N-2-hydroxyethyl
piperazine-N'-2-ethanesulphonic acid (HEPES) buffer, pH 7.5, containing 100 mM
glycine, 100 mM glutamate, 1 mM ethylenediaminetetraacetic acid (EDTA) and 20
nM [3H]MK-801 (specific activity 17.1 Ci/mmol, Perkin Elmer, Boston,
Massachusetts, USA). Nonspecific binding was determined by incubating adjacent
sections with [3H]MK-801 in the presence of 20 mM MK-801. Following incubation,
sections were washed twice for 20 min each at 0ºC in 30 mM HEPES containing 1
mM EDTA (pH 7.5). Autoradiographic images for NMDA receptor binding were
taken using a Beta-ImagerTM camera (BioSpace, Paris, France). Sections were
scanned for 3.5 hr at a high-resolution setting. A series of sections with known
amount of radioactivity were used as standards in all scans. Quantitative analysis of
these images was performed using the program β-Image Plus (version 4, BioSpace).

2.5 GABAA receptor binding
The method for GABAA receptor binding followed that of Newell et al. (2007).
Sections were pre-incubated three times for 5 min at 4ºC in 50 mM Tris-citrate (pH
7). Sections were then incubated for 45 min at 4ºC in the same buffer containing 3 nM
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[3H]muscimol (specific activity 29.5 Ci/mmol; PerkinElmer, USA). Non-specific
binding was determined by the addition of 100 µM GABA to adjacent sections.
Following incubation, sections were rinsed four times for 2 s in 4ºC buffer and dried
in a stream of cool air. Sections were opposed to Kodak BioMax MR film with
Amersham microscales for 12 weeks. Autoradiographs were developed using Kodak
GBX developer and fixed with Kodak GBX fixer. Autoradiographic images were
captured and analysed using a computer-assisted image analysis system, MultiAnalyst, connected to a GS-690 Imaging Densitometer (Bio-Rad, California).

2.6 Quantification
A set of sections from each age and treatment group were stained with cresyl violet
for confirmation of anatomical structures. Specific binding was calculated by
subtracting non-specific binding from total binding. Non-specific binding was less
than 30% of total binding. The data presented is the average of three brain sections
from each of the six rats per group. Areas quantified included the prefrontal and
anterior cingulate cortices, the ventral thalamus and hippocampus. Sub-regions of the
hippocampus (CA1-3) were quantified, but no differences were found so the mean of
the sub-regions was used in the results.

2.7 Statistical Analyses
Statistical analyses were performed using SPSS (version 15.0, SPSS Inc., Chicago).
Two-way (age x treatment) ANOVAs were used to analyse NMDA and GABAA
receptor binding among individual brain regions. Unpaired two-tailed t-tests were
used to compare binding across developmental time-points and for comparing binding
in PCP and control groups at individual time-points. Pearson’s correlations were used
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to examine the relationship between NMDA and GABAA receptor binding at
individual time-points in overall groups. Data is expressed as means ± S.E.
Significance was set at p<0.05. The measurement of radioligand binding signals is
presented in fmoles/mg of tissue equivalent.

3. RESULTS
3.1 NMDA receptor binding across developmental time-points
Prefrontal cortex
In the prefrontal cortex, there were significant main effects of age (F3, 34 = 107.35,
p<0.001) and treatment (F1, 34 = 23.20, p<0.001), as well as interaction between the
two factors (F3, 34 = 4.23, p<0.01). NMDA receptor binding significantly increased
with age in the control group from PN12 to PN96 (p<0.01). In the PCP group binding
also progressively increased but this was only significant from PN12 to PN18
(p<0.001). In terms of treatment effects, NMDA receptor binding was significantly
increased in PCP-treated rats at PN18 (18%, p<0.001) and 32 (16%, p<0.05)
compared to controls (Fig. 1A). At PN96 there was no change compared to controls.

Anterior cingulate cortex
The anterior cingulate cortex also showed significant main effects of age (F3, 37 =
191.29, p<0.001) and treatment (F1, 37 =25.21, p<0.001), as well as interaction
between the two factors (F3, 37 = 28.81, p<0.001). In terms of age differences, NMDA
receptor binding progressively increased significantly until PN96 in the control group
(p<0.05). Conversely, in the PCP group, binding significantly increased until PN32
(p<0.001) and then declined at PN96 (p<0.01). Perinatal PCP treatment had the effect
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of significantly increasing NMDA receptor binding (Fig. 1B) at PN32 only (37%,
p<0.001; Fig. 2A, B) compared to controls.

Thalamus
In the thalamus there were significant main effects of age (F3, 40 = 263.7, p<0.001)
and treatment (F1, 40 =95.0, p<0.001), as well as interaction between the two factors
(F3, 40 = 12.7, p<0.001). The control group displayed a temporal pattern whereby
binding increased from PN12 to PN18 (p<0.001) then increased slightly more from
PN32 to PN96 (p<0.05). The PCP-treated group also showed a large increase in
binding from PN12 to PN18 (p<0.001), but this was then followed by a further
increase at PN32 (p<0.01) with no change at PN96. In terms of treatment effects,
there were increases in NMDA receptor binding at PN18 (12%), PN32 (29%) and
PN96 (22%) compared to the control group (p’s <0.001; Fig. 1C).

Hippocampus
In the hippocampus there was a main effect of age (F3,40 = 283.52, p<0.001) but not
treatment (F1,40 = 0.186, p=0.669), although there was significant interaction between
the two factors (F3,40 = 17.78, p<0.001). Control rats showed an increase in binding
up until PN32 (p<0.01) and PCP rats showed progressive increases in binding until
PN96, significant at all points (p<0.001) except from PN18 to PN32. Perinatal PCP
treatment increased NMDA receptor binding by 14% at adulthood only, compared to
controls (p<0.001; Fig 1D).

3.2 GABAA receptor binding across developmental time-points
Prefrontal cortex
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In the PFC, there were significant main effects of age (F3,38 = 66.7; p<0.001) and
treatment (F1,38 = 18.1; p<0.001) on GABAA receptor binding, as well as significant
interaction between the two factors (F3,38 = 11.7; p<0.001). In terms of age effects, the
control group generally showed increased binding until PN96 (p<0.05). In the PCP
group, binding increased with age from PN18 to PN32 (p<0.05) then remained
unchanged. In terms of treatment effects, PCP-treated rats showed increased GABAA
receptor binding levels compared to controls at PN32 (43%; p<0.001), while there
were no differences at the other time-points (Fig. 1E).

Anterior cingulate cortex
In the ACC, there was a significant main effect of age (F3,39 = 30.5; p<0.001) but not
treatment, although there was a significant interaction between the two factors (F3,39 =
15.0; p<0.001). When looking at the temporal pattern of GABAA receptor binding,
control rats showed increased binding levels at PN18 (p<0.05), followed by a further
increase at PN96 (p<0.01). In PCP-treated rats, GABAA receptor binding increased
with age until PN32 (p<0.05), after which it significantly declined (p<0.001). Similar
to the prefrontal cortex, GABAA receptor binding levels were significantly elevated
(59%; p<0.001; Fig. 2C, D) in PCP-treated rats compared to controls at PN32, while
there were no significant differences at other time-points (Fig. 1F).

Thalamus
In the thalamus, there were significant main effects of age (F3,34 = 70.0; p<0.001) and
treatment (F1,34 = 44.8; p<0.001) on GABAA receptor binding, as well as significant
interaction between the two factors (F3,34 = 6.5; p<0.001). In terms of age effects, the
control group showed no changes in the level of GABAA receptor binding until PN96
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when levels significantly declined (p<0.001). Conversely, in PCP-treated rats, binding
was significantly increased at PN18 and 32 compared PN12 (p<0.01), and binding
was significantly lower at PN96 than all other ages (p<0.001). In terms of treatment
effects, GABAA receptor binding was significantly elevated (27-47%; p<0.01) in
PCP-treated rats compared to controls at all ages from PN18 onwards (Fig 1G).

Hippocampus
In the hippocampus, there were significant main effects of age (F3,34 = 79.5; p<0.001)
and treatment (F1,34 = 28.9; p<0.001) on GABAA receptor binding, as well as
significant interaction between the two factors (F3,34 = 4.8; p<0.01). When looking at
the temporal pattern of GABAA receptor binding, control rats showed a reduction in
binding at PN32 (p<0.05) and PN96 (p<0.001) compared to earlier time-points. PCPtreated rats showed a different pattern of binding, with an increase at PN18 (p<0.01),
followed by reductions at PN32 and PN96 (p<0.001). Similar to what was observed in
the thalamus, the PCP-treated group showed increased GABAA receptor binding
compared to controls (22-45%; p<0.05) at all time-points from PN18 onwards (Fig
1H).

3.3 The relationship between NMDA and GABAA receptor binding in brain regions
examined
GABAA receptor binding levels were highly correlated with NMDA receptor binding
levels in the brain regions and time-points that both NMDA and GABAA receptor
binding were changed. There were significant positive correlations between NMDA
and GABAA receptor binding at PN32 in the prefrontal (r=0.876, p<0.001) and
anterior cingulate (r=0.934, p<0.001) cortices (Fig. 3A, B). In the thalamus, there was
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a significant positive correlation between NMDA and GABAA receptor binding at
PN18 (r=0.614, p<0.05), 32 (r=0.751, p<0.01) and 96 (r=0.829, p<0.01; Fig. 3C).
Finally, in the hippocampus, there was a significant positive correlation between
NMDA and GABAA receptor binding at PN96 (r=0.919, p<0.001; Fig3D).

4. DISCUSSION
The present study examined how NMDA and GABAA receptor binding are altered
during the course of brain development following perinatal PCP treatment. We found
that the pattern of change of these two systems was remarkably similar and highly
correlated in all regions examined, highlighting the close relationship between the two
systems. In PCP-treated rats, the thalamus and hippocampus both showed increased
NMDA and GABAA receptor binding levels compared to controls, which were still
evident at adulthood. The prefrontal and anterior cingulate cortices also showed
increased binding of these two receptors, mainly at adolescence. Control rats
displayed developmental patterns of [3H]MK-801 and [3H]muscimol binding that are
consistent with previous reports from the literature (Facchinetti et al. 1993; Insel et al.
1990; Morin et al. 1989; Xia and Haddad 1992).

Perinatal administration of NMDA receptor antagonists is known to induce massive
increases in neuronal apoptosis (Fredriksson et al. 2004; Hansen et al. 2004; Harris et
al. 2003; Ikonomidou et al. 1999; Wang et al. 2001). In fact, using corticostriatal
slices from PN7 rats, Wang et al. (2005) showed that PCP-induced apoptosis required
upregualtion of NR1 and NR2A polypeptides. Co-incubation of PCP with an
antisense oligodeoxynucleotide specific to the NR1 and NR2A mRNAs prevented
both PCP-induced NR1 and NR2A upregulation and cortical DNA fragmentation. We
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did not observe any NMDA receptor binding changes at PN12. It is possible that the
concomitant effects of apoptosis and NMDA receptor upregulation balance out any
overall change in binding 24hrs after treatment cessation. Alternatively, changes in
receptor expression levels may require more time to become evident at the protein
level.

Wang et al. (2001) reported increased expression of NR1 one day after cessation of
perinatal PCP treatment in the basal forebrain and not the hippocampus. In addition,
an acute study where rats were treated with MK-801 on PN7 showed that expression
of the obligatory NMDA receptor subunit, NR1, was increased in the ventral part of
the hippocampus in adulthood (Harris et al. 2003). These results are consistent with
our binding results that show NMDA receptor upregualtion in cortical regions shortly
following treatment and upregualtion of binding in the hippocampus in adulthood. No
studies on the effects of perinatal NMDA receptor blockade on [3H]muscimol binding
are available in the literature for comparison. It is unclear why the prefrontal and
anterior cingulate cortices only showed changes at adolescence while the thalamus
and hippocampus were affected at all time-points from PN18 onwards. The varying
response of different brain regions to PCP treatment may be due to innate differences
in organisation and connectivity (Benes 2000), as well as differences in temporal
expression of NMDA and GABAA receptors. The observation that certain regions are
affected only at adolescence, and that this time-point shows the greatest magnitude of
change suggests an increased vulnerability of the brain to further adverse impacts at
this developmental stage.
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An explanation for the sustained increase in NMDA and GABAA receptor binding
seen in PCP-treated rats is that perinatal NMDA receptor blockade could lead to a loss
of or improper wiring of glutamatergic neurons and a decrease in glutamatergic
transmission. This would be expected to cause a compensatory upregulation of
NMDA receptors. Decreased glutamatergic activation of NMDA receptors, as well as
AMPA and kainate receptors on GABAeric interneurons would be expected to reduce
activity of those cells, thereby decreasing GABA release and causing compensatory
increase in GABAA receptor levels. This could explain the strong positive correlation
between NMDA and GABAA receptor binding observed in the present study.
Investigation of AMPA and kainate receptor densities following perinatal PCP
treatment would help to clarify the contribution of glutamate levels to PCP-induced
pathology.

Alternatively, blockade of NMDA receptors during the critical period of receptor
sensitivity could by some unknown mechanism, cause an upregulation of NMDA
receptors which never returns to normal. This blockade could also selectively destroy
specific GABAergic neuronal populations, and therefore a decrease in the number of
GABA-producing cells may lead to an upregulation of GABAA receptors. In support
of this, Wang et al. (2007) found that perinatal PCP treatment resulted in the selective
loss of parvalbumin-containing interneurons in cortical brain regions in early
adulthood. However, the widespread upregulation of GABAA in the present study
suggests that perhaps a combination of both deficits in glutamatergic transmission and
loss of specific neuronal populations contribute to increased binding of both NMDA
and GABAA receptors.
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A loss of or decreased stimulation GABAegic cells would presumably lead to
disinhibition and over-excitation of pyramidal neurons. In the prefrontal cortex, a
reduction in GABAergic transmission would reduce inhibitory inputs to pyramidal
neurons, resulting in less filtering of noise, which could contribute to cognitive
deficits seen in this model (Andersen and Pouzet 2004; Wang et al. 2001; Wiley et al.
2003). Similarly, in schizophrenia, disinhibition of pyramidal neurons through a loss
of GABAergic outputs is thought to contribute to symptoms of the disorder (Lisman
et al. 2008). In the hippocampus, disinhibition of pyramidal neurons could elevate
activity of ventral tegmental area (VTA) neurons. This elevation of VTA activity has
been shown to occur in another schizophrenia animal model which has deficits in
hippocampal interneurons caused by prenatal methylazoxymethanol acetate (MAM)
administration, and can be reversed by inactivating the subiculum (Lodge and Grace
2007). This is consistent with our previous findings of elevated tyrosine hydroxylase
mRNA expression in the VTA, and decreased D2 receptor binding in striatum
following perinatal PCP treatment, which we suggest reflects increased dopamine
output from the VTA (du Bois et al. 2008a).

Our finding that perinatal blockade of NMDA receptors may lead to long-term
deficits in glutamatergic and GABAergic neurotransmission is relevant to
schizophrenia pathology and treatment. Interestingly, co-administering agents that
enhance GABAergic transmission with antipsychotic drugs provide more effective
therapy to schizophrenia patients than antipsychotics alone (Casey et al. 2003; Wassef
et al. 2000), including in treatment-resistant patients (Dursun and Deakin 2001;
Tiihonen et al. 2003). Moreover, agents which enhance NMDA receptor channel
activity such as agonists of the glycine binding site (eg. D-cycloserine, glycine and D-
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serine), and sarcosine, a glycine transport inhibitor, have had good success in treating
when co-administered with antipsychotic drugs (Coyle and Tsai 2004; Lane et al.
2006; Tsai et al. 2004). In addition, it has been recently shown that an mGlu2/3
agonist is effective alone in treating symptoms (Patil et al. 2007), and part of the
effect may be related to enhancement of postsynaptic NMDA receptor function
(Tyszkiewicz et al. 2004). Recently, Andersen and Pouzet (2004) showed that
cognitive impairments in the Morris water maze task resulting from perinatal PCP
treatment of Sprague-Dawley rats could be reversed with chronic D-serine treatment,
which further supports the idea of NMDA receptor hypofunction in this model and
has good predictive validity for schizophrenia.

In summary, this study has shown that blockade of NMDA receptors persistently
affects NMDA and GABAA receptor binding levels during the course of brain
development. It would appear that the binding changes reflect deficits in excitatory
and inhibitory neurotransmission, consistent with what has been reported by others in
this model. This could result in the disinihibition of pyramidal neurons, which would
have flow on effects such as causing a hyperdopaminergic state. Further studies
examining these possibilities are required before any firm conclusions can be made.
The perinatal NMDA receptor antagonist treatment model therefore represents some
of the possible disease processes that may be involved in psychiatric disorders such as
schizophrenia.
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Figure legends:
Figure 1. NMDA receptor binding (A-D) and GABAA receptor binding (E-H) in PCPtreated and control rats across developmental time-points. Abbreviations: ACC,
anterior cingulate cortex; GABAAR, GABAA receptor; Hipp, hippocampus;
NMDAR, NMDA receptor; PCP, phencyclidine; PFC, prefrontal cortex; PN,
postnatal day, Thal, thalamus. *p<0.05 vs. control at individual time-point.

Figure 2. NMDA receptor binding is shown in the anterior cingulate cortex of control
(A) and PCP-treated (B) groups at PN32. Similarly, GABAA receptor binding is
shown in the anterior cingulate cortex control (C) and PCP-treated (D) groups at
PN32, where the greatest magnitude of change in NMDA and GABAA receptor
binding was observed. Abbreviations: ACC, anterior cingulate cortex; PCP,
phencyclidine; PN, postnatal day.

Figure 3. Correlation between GABAA and NMDA receptor binding in the anterior
cingulate and prefrontal cortices at PN32 (A and B) and in the thalamus and
hippocampus at PN96 (C and D). Control rats are indicated by the square markers and
PCP-treated rats by the diamond markers. Abbreviations: ACC, anterior cingulate
cortex; Hipp, hippocampus; PFC, prefrontal cortex; PN, postnatal day; Thal,
thalamus.
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